Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cost of Revenue: 2021-2025

Historic Cost of Revenue for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Sep 2025 value amounting to $8.3 million.

  • Tarsus Pharmaceuticals' Cost of Revenue rose 156.29% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 170.77%. This contributed to the annual value of $12.8 million for FY2024, which is 705.15% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Cost of Revenue is $8.3 million, which was up 33.22% from $6.2 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Cost of Revenue's 5-year high stood at $8.3 million during Q3 2025, with a 5-year trough of -$24,000 in Q4 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $3.2 million (2024), whereas its average is $3.8 million.
  • Over the last 5 years, Tarsus Pharmaceuticals' Cost of Revenue had its largest YoY gain of 1,766.67% in 2022, and its largest YoY loss of 97.46% in 2022.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Cost of Revenue stood at -$24,000 in 2021, then spiked by 1,766.67% to $400,000 in 2022, then skyrocketed by 204.00% to $1.2 million in 2023, then surged by 305.10% to $4.9 million in 2024, then skyrocketed by 156.29% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $6.2 million for Q2 2025, and $5.2 million during Q1 2025.